Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
NOT YET RECRUITING
NCT06746753
PHASE4

Mechanistic Assessment of Norepinephrine Therapy vs. Angiotensin-II in Septic Shock

Sponsor: Wake Forest University Health Sciences

View on ClinicalTrials.gov

Summary

Despite best therapy efforts, sepsis and septic shock are associated with mortality rates of up to 40%. This clinical trial will determine the benefit of exogenous Angiotensin II versus norepinephrine (conventional care) treatment in septic shock patients. This trial will determine whether there are better predictors of septic shock severity. This approach may inform more appropriate treatment regimens and improve outcomes for these patients.

Official title: Mechanistic Assessment of Norepinephrine TheRapy vs. Angiotensin-II in Septic Shock (MANTRA) Grant Submission- Dysfunctional Renin-Angiotensin System in Septic Shock

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

78

Start Date

2026-05

Completion Date

2028-08

Last Updated

2026-03-31

Healthy Volunteers

No

Conditions

Interventions

DRUG

Angiotensin II

randomized to receive Angiotensin II continuous infusion for up to 48 hours

DRUG

Norepinephrine

randomized to receive Norepinephrine continuous infusion for up to 48 hours

Locations (2)

Massachusetts General Hospital-Harvard

Boston, Massachusetts, United States

Atrium Health Wake Forest Baptist

Winston-Salem, North Carolina, United States